Medivir’s MIV-711 Receives FDA ODD and RPDD for Legg-Calvé-Perthes Disease
Shots:
- US FDA granted ODD and RPDD to Medivir’s MIV-711 for treatment of Legg-Calvé-Perthes Disease (LCPD)
- Animal model of LCPD shown the ability to prevent femoral head deformity and positive impact on bone degradation biomarker without affecting bone formation. Common consequences of LCPD in children includes Obesity, Depression, and Osteoarthritis
- With RPDD, MIV-711 is eligible for fast-track review and Priority review voucher post-FDA approval for LCPD
Ref: Medivir | Image: Medivir
Related News:- Medivir AB Reports the First Patient Dosing of Fostrox + Lenvima in P-IIa Trial for the Treatment of Hepatocellular Carcinoma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
